Sourav Bandyopadhyay, PhD

Professor
Bioengineering
+1 415 476-3425
Research Overview: 

The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
None
Research Summary: 
Computational and experimental approaches to guide the development of new precision medicines for cancer
Mentorship Development: 

11/10/20    Optimizing the Efficiency of Your Lab

Websites

Publications: 

UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.

Proceedings of the National Academy of Sciences of the United States of America

Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE

Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Clinical cancer research : an official journal of the American Association for Cancer Research

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR

Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.

Journal of Clinical Oncology

Collin M. Blakely, Matthew A. Gubens, Gregory M. Allen, Shrusti Shah, Matthew Jereza, Bianca Bacaltos, Sourav Bandyopadhyay

Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK.

Molecular cancer therapeutics

Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL